We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
Alzheimer's specialists have identified a potential early sign of dementia that could transform the speed at which the ...
Tested in animal models, it may extend cognitive function by 10-15 years, offering a potential breakthrough in Alzheimer’s ...
As people age, the body changes as part of the normal ageing process, such as greying hair and loss of elasticity in the skin ...
Analysis of human brain tissue revealed differences in how immune cells behave in brains with Alzheimer's disease compared to ...
H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating today. Patrick ...
Officials said over 71,000 Oklahomans are currently living with Alzheimer's disease. Nationally, that number is approaching 7 ...
Research suggests that omega-3s can support brain health, especially for people who carry a gene that raises the risk of ...
Trajectories of frailty increased more rapidly 4 to 9 years before dementia onset. Even before this acceleration, higher ...
For so long, we had a drought when it came to treatment options for Alzheimer's, until the last few years when we've seen two ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...